Paradiem LLC Has $8 Million Stake in Cabot Co. (NYSE:CBT)

Paradiem LLC increased its position in shares of Cabot Co. (NYSE:CBT) by 37.3% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 95,778 shares of the specialty chemicals company’s stock after buying an additional 26,043 shares during the quarter. Cabot accounts for about 2.2% of Paradiem LLC’s portfolio, making the stock its 8th biggest holding. Paradiem LLC’s holdings in Cabot were worth $7,997,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of CBT. Arlington Trust Co LLC bought a new position in Cabot in the fourth quarter valued at approximately $34,000. GAMMA Investing LLC bought a new position in Cabot in the fourth quarter valued at approximately $44,000. Milestone Investment Advisors LLC bought a new position in Cabot in the third quarter valued at approximately $79,000. NBC Securities Inc. bought a new position in Cabot in the third quarter valued at approximately $162,000. Finally, Blue Trust Inc. boosted its stake in shares of Cabot by 33.4% during the 4th quarter. Blue Trust Inc. now owns 2,527 shares of the specialty chemicals company’s stock worth $211,000 after acquiring an additional 632 shares during the period. 93.18% of the stock is currently owned by institutional investors.

Cabot Stock Performance

NYSE:CBT traded up $0.56 during mid-day trading on Friday, hitting $93.59. 173,821 shares of the stock were exchanged, compared to its average volume of 259,962. The stock has a market capitalization of $5.19 billion, a price-to-earnings ratio of 12.15, a price-to-earnings-growth ratio of 0.99 and a beta of 1.28. The firm’s 50-day simple moving average is $89.46 and its 200 day simple moving average is $80.61. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.30 and a current ratio of 2.04. Cabot Co. has a fifty-two week low of $63.73 and a fifty-two week high of $98.34.

Cabot (NYSE:CBT) last announced its quarterly earnings data on Monday, February 5th. The specialty chemicals company reported $1.56 earnings per share for the quarter, beating the consensus estimate of $1.49 by $0.07. The firm had revenue of $958.00 million during the quarter, compared to analysts’ expectations of $927.28 million. Cabot had a return on equity of 25.52% and a net margin of 11.24%. As a group, equities analysts anticipate that Cabot Co. will post 6.58 EPS for the current fiscal year.

Insider Buying and Selling at Cabot

In other Cabot news, EVP Jeff Ji Zhu sold 55,233 shares of Cabot stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $79.91, for a total value of $4,413,669.03. Following the completion of the transaction, the executive vice president now directly owns 97,201 shares of the company’s stock, valued at approximately $7,767,331.91. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 3.07% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. Mizuho assumed coverage on Cabot in a research note on Wednesday, March 27th. They set a “buy” rating and a $104.00 target price for the company. StockNews.com downgraded Cabot from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, February 14th. Deutsche Bank Aktiengesellschaft downgraded Cabot from a “buy” rating to a “hold” rating and lifted their target price for the stock from $88.00 to $95.00 in a research note on Thursday, April 18th. Finally, UBS Group downgraded Cabot from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $90.00 to $87.00 in a research note on Monday, January 8th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $90.17.

About Cabot

Cabot Corporation operates as a specialty chemicals and performance materials company. The company operates through two segments, Reinforcement Materials and Performance Chemicals. It offers reinforcing carbons that are used in tires as a rubber reinforcing agent and performance additive, as well as in industrial products, such as hoses, belts, extruded profiles, and molded goods; and engineered elastomer composites solutions.